CJC-1295 vs Sermorelin
CJC-1295 and sermorelin are both growth hormone-releasing hormone (GHRH) analogs that stimulate endogenous GH secretion via the GHRH receptor on anterior pituitary somatotrophs. However, they differ fundamentally in their molecular engineering: sermorelin is the native 1-29 fragment of human GHRH, while CJC-1295 is a synthetically modified analog with enhanced stability and, in its DAC form, dramatically extended half-life. These differences produce distinct pharmacokinetic profiles, pulsatility characteristics, and clinical utility.
Chemical Identity
Section titled “Chemical Identity”Sermorelin
Section titled “Sermorelin”Sermorelin (GHRH(1-29)NH₂) is the shortest biologically active fragment of human GHRH, comprising the first 29 amino acids with an amidated C-terminus. Sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSR-amide. Molecular weight: 3358 Da. It retains full biological activity of the native 44-amino acid GHRH molecule because the N-terminal 1-29 region contains all residues necessary for receptor binding and activation. Marketed as Geref (Serostim for HIV-related wasting).
CJC-1295
Section titled “CJC-1295”CJC-1295 is a synthetic analog of GHRH(1-29) with two key modifications: D-Ala² substitution and a Heza (hexaethylene glycol) modification. These changes protect against DPP-IV enzymatic degradation. Without DAC (CJC-1295 no-DAC), the half-life is ~30-40 minutes. With Drug Affinity Complex (DAC) conjugation (CJC-1295-DAC), the peptide binds endogenous albumin, extending the half-life to ~6-8 days. Sequence: Y-Aib-Ada-βAla-Tyr-DAla-Arg-MeAla-Ada-βAla-Arg-MeAla-Aib-Gln-DAla-Ala-Arg-MeAla-Lys-Pro-Val-amide (approximate). Molecular weight: ~3647 Da (no-DAC); ~4400 Da (with DAC).
Mechanism of Action
Section titled “Mechanism of Action”GHRH Receptor Activation
Section titled “GHRH Receptor Activation”Both peptides bind the GHRH receptor (GHRHR) on anterior pituitary somatotrophs. GHRHR is a Gs-protein-coupled receptor that activates:
- Adenylyl cyclase → increased cAMP
- Protein kinase A (PKA) → phosphorylation of CREB
- CREB activation → GH gene transcription
- Calcium influx → vesicular GH exocytosis
The N-terminal region (residues 1-29) of both peptides contains the receptor-binding domain (residues 1-19) and the effector domain (residues 20-29) responsible for Gs activation.
Key Differences in Activation
Section titled “Key Differences in Activation”| Feature | Sermorelin | CJC-1295 |
|---|---|---|
| Binding affinity | Native affinity (Kd ~1-5 nM) | Slightly reduced (D-Ala² modification) |
| Receptor activation | Full agonist | Full agonist |
| Gs coupling | Normal | Normal |
| cAMP production | Normal | Normal |
| GH transcription | Normal | Normal |
| DPP-IV resistance | Low (t₁/₂ ~6-8 min) | High (D-Ala² protects N-terminus) |
| Receptor desensitization | Moderate (continuous exposure) | Reduced (with DAC: sustained; no-DAC: pulsatile) |
Half-Life Engineering
Section titled “Half-Life Engineering”Sermorelin: Short-Acting
Section titled “Sermorelin: Short-Acting”Sermorelin’s half-life is approximately 6-8 minutes in vivo, dominated by:
- DPP-IV cleavage: Preferential cleavage between Ala²-Asp³ (native Gln² is susceptible)
- Renal clearance: Rapid glomerular filtration of the small peptide
- Receptor internalization: Rapid GHRHR-mediated endocytosis
This short half-life means sermorelin produces discrete GH pulses that closely mimic physiological secretion patterns, with return to baseline between pulses.
CJC-1295: Extended via Albumin Binding
Section titled “CJC-1295: Extended via Albumin Binding”CJC-1295’s modifications create a spectrum of half-lives:
| Formulation | Half-Life | Mechanism |
|---|---|---|
| CJC-1295 no-DAC | 30-40 min | D-Ala² resists DPP-IV; Heza adds steric protection |
| CJC-1295-DAC | 6-8 days | DAC binds albumin; sustained exposure |
The DAC conjugation involves a reactive moiety that forms a covalent bond with Lys34 of circulating albumin. This creates a circulating reservoir that slowly releases the active peptide. The albumin-binding effectively increases the apparent volume of distribution and reduces renal clearance.
GH Release Patterns
Section titled “GH Release Patterns”Sermorelin: Physiological Pulsatility
Section titled “Sermorelin: Physiological Pulsatility”Sermorelin produces GH release patterns that most closely resemble natural secretion:
- Pulse frequency: 6-8 pulses per 24 hours (when dosed 3x daily)
- Pulse amplitude: 15-30 ng/mL per pulse
- Pulse duration: 1-2 hours
- Trough levels: Return to baseline between pulses
- Nocturnal predominance: Enhanced pulsatility during sleep
- Self-limiting: GH/IGF-1 negative feedback intact
CJC-1295 no-DAC: Enhanced Pulsatility
Section titled “CJC-1295 no-DAC: Enhanced Pulsatility”Without DAC, CJC-1295 produces enhanced pulsatile release:
- Pulse frequency: Same as dosing frequency (1-3x/day)
- Pulse amplitude: 15-25 ng/mL per pulse
- Pulse duration: 2-4 hours (longer than sermorelin due to DPP-IV resistance)
- Trough levels: Near baseline between doses
- GH total area: Greater than sermorelin per equivalent dose
CJC-1295-DAC: Sustained Elevation
Section titled “CJC-1295-DAC: Sustained Elevation”With DAC conjugation, the pattern shifts dramatically:
- GH profile: Sustained elevation rather than discrete pulses
- Peak GH: 10-20 ng/mL sustained over 24-48 hours
- No return to baseline: Continuous GH exposure
- IGF-1 elevation: 30-50% above baseline sustained
- Pulsatility: Lost — continuous GHRHR stimulation
Receptor Pharmacology Comparison
Section titled “Receptor Pharmacology Comparison”| Property | Sermorelin | CJC-1295 |
|---|---|---|
| GHRHR binding | High affinity (native) | High affinity (modified) |
| Gs coupling | Normal | Normal |
| cAMP elevation | Normal | Normal |
| GH gene transcription | Normal | Normal |
| Receptor internalization | Rapid | Moderate |
| Desensitization risk | Moderate (dose-dependent) | Lower (modified structure) |
| Somatotroph hyperplasia | Theoretical with chronic use | Theoretical with chronic use |
| GH pool effect | Transcription + release | Transcription + release |
IGF-1 Elevation
Section titled “IGF-1 Elevation”| Parameter | Sermorelin | CJC-1295 no-DAC | CJC-1295-DAC |
|---|---|---|---|
| Peak IGF-1 | 20-35% above baseline | 25-40% above baseline | 30-50% above baseline |
| Time to peak IGF-1 | 12-24 hours | 12-24 hours | 48-72 hours |
| Duration of elevation | 24-48 hours | 24-48 hours | 7-14 days |
| Steady state (repeated dosing) | 3-5 days | 3-5 days | 2-3 weeks |
| Feedback suppression | Moderate | Moderate | Higher (sustained) |
Dosing Protocols
Section titled “Dosing Protocols”Sermorelin
Section titled “Sermorelin”| Parameter | Standard Protocol |
|---|---|
| Dose | 0.3-1.0 mg SC |
| Frequency | 1-3x daily (at bedtime preferred) |
| Timing | Bedtime (mimics nocturnal GH surge) |
| Cycle | 3 months on, 1 month off |
| Route | Subcutaneous |
CJC-1295 no-DAC
Section titled “CJC-1295 no-DAC”| Parameter | Standard Protocol |
|---|---|
| Dose | 30-60 µg/kg SC |
| Frequency | 1-3x daily |
| Timing | Morning or pre-sleep |
| Cycle | 3-6 months |
| Route | Subcutaneous |
CJC-1295-DAC
Section titled “CJC-1295-DAC”| Parameter | Standard Protocol |
|---|---|
| Dose | 30 µg/kg SC |
| Frequency | 1-2x per week |
| Timing | Any time |
| Cycle | 3-6 months |
| Route | Subcutaneous |
Approval and Regulatory Status
Section titled “Approval and Regulatory Status”Sermorelin
Section titled “Sermorelin”- FDA approved: Yes (Geref) for GH deficiency diagnosis and HIV wasting
- Clinical trials: Multiple Phase 3 trials in GH deficiency
- Commercial availability: Available in some markets (discontinued in US)
- Research status: Well-characterized safety profile
CJC-1295
Section titled “CJC-1295”- FDA approved: No
- Clinical trials: Phase 1-2 completed; no Phase 3 as of 2025
- Commercial availability: Research chemical only
- Regulatory status: Not approved for human use in any jurisdiction
- Safety data: Limited to small Phase 1-2 studies
Side Effect Profiles
Section titled “Side Effect Profiles”Sermorelin
Section titled “Sermorelin”- Injection site reactions (redness, swelling)
- Facial flushing
- Headache (mild, transient)
- Dizziness
- Nausea (rare)
- Taste changes
- No cortisol elevation
- No significant hormonal side effects
CJC-1295
Section titled “CJC-1295”- Injection site reactions
- Facial flushing
- Headache
- Diarrhea (more common with DAC)
- Numbness/tingling (paresthesias)
- Possible fluid retention at high doses
- Theoretical concern: sustained GHRH stimulation → somatotroph hyperplasia
- No cortisol elevation
Combination Considerations
Section titled “Combination Considerations”When CJC-1295 is combined with GHSR1a agonists (ipamorelin, GHRP-6):
- Synergistic GH release exceeding either agent alone
- Higher IGF-1 elevation
- No additive hormonal side effects
- Enhanced safety profile (cortisol-neutral combination)
When to Choose Which
Section titled “When to Choose Which”Sermorelin may be considered when:
- Physiological pulsatile GH release is the goal
- GH deficiency diagnosis is needed
- Short-acting agent preferred for cycling
- FDA-approved therapy is desired
- Cost is a primary concern
CJC-1295 no-DAC may be considered when:
- Enhanced pulsatility with longer action than sermorelin is desired
- DPP-IV resistance is important
- More convenient dosing (2-3x daily vs 3x) is preferred
- Combination with GHSR1a agonists is planned
CJC-1295-DAC may be considered when:
- Maximum convenience (1-2x/week dosing) is desired
- Sustained GH/IGF-1 elevation is the goal
- Continuous exposure rather than pulsatility is acceptable
- Research context with limited safety data is acceptable
References
Section titled “References”- Giustina A, et al. “Growth hormone-releasing hormone and growth hormone secretagogues.” Pituitary 1998;1:119-129.
- Teichman SL, et al. “A novel GHRH analogue (CJC-1295) produces sustained GH elevation.” J Clin Endocrinol Metab 2006;91:3478-3485.
- Camillis JA, et al. “CJC-1295-DAC: pharmacokinetics and GH stimulation.” J Endocrinol Invest 2004;27:RC13-16.
- Ionescu M, et al. “Sermorelin in the diagnosis of GH deficiency.” J Clin Endocrinol Metab 1998;83:3054-3060.
- Thorner MO, et al. “Growth hormone-releasing hormone therapy.” Endocr Rev 1993;14:184-194.